Related Experiment Videos

NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial

Maqsood Elahi1, Sanjay Asopa, Bashir Matata

  • 1Wessex Cardiothoracic Centre, Chalybeate Close, Southampton, SO16 6UY, UK.

Biochimica Et Biophysica Acta
|October 19, 2006
PubMed

Insights

Sustained nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) over-expression contribute to heart failure progression. Their cross-regulation in cardiac hypertrophy and dysfunction highlights potential therapeutic targets.

Area of Science:

  • Cardiovascular Pathophysiology
  • Molecular Cardiology
  • Heart Failure Research

Background:

  • Heart failure progression linked to over-expression of nitric oxide (NO) metabolites via inducible nitric oxide synthase (iNOS).
  • Over-expression of tumor necrosis factor-alpha (TNF-alpha) also identified as a contributor to heart failure phenotype.
  • Established cardiovascular interactions between TNF-alpha and NO, with recent focus on their role in cardiac hypertrophy.

Purpose of the Study:

  • To review updated evidence on the cross-regulation between NO and TNF-alpha signaling in blood.
  • To elucidate the role of this interaction in cardiac hypertrophy and heart failure.
  • To discuss the therapeutic potential of targeting these pathways.

Main Methods:

  • Literature review of updated evidence on NO and TNF-alpha interactions.
  • Analysis of their signaling pathways in the context of cardiac hypertrophy.
  • Synthesis of findings related to therapeutic interventions.

Main Results:

  • Evidence suggests a functionally significant cross-regulation between NO and TNF-alpha signaling.
  • This interaction contributes to left ventricular (LV) remodeling, hypertrophy, and dysfunction.
  • Over-expression of both NO metabolites and TNF-alpha are implicated in disease progression.

Conclusions:

  • NO and TNF-alpha signaling pathways are intricately linked in cardiac hypertrophy and failure.
  • Targeting these pathways may offer therapeutic strategies for reducing cardiomyocyte hypertrophy and LV dysfunction.
  • Understanding these interactions is crucial for advancing heart failure treatment.

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...